Sweden Archives

aprea therapeutics anti cancer protein cover

News and Trends 3 Dec 2018

First-in-Class Cancer Drug Gets €50M Boost

The biopharmaceutical company Aprea Therapeutics has raised €50M to fund a Phase III trial of its first-in-class cancer drug candidate, which kills tumor cells by restoring the function of a key anti-cancer protein called p53. Aprea’s planned Phase III trial will test the company’s lead candidate small molecule drug combined with the chemotherapy drug azacitidine. […]

December 3, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 30 Nov 2018

Swedish Researchers Recycle Industrial Food Waste to Grow Fungi

Researchers at the University of Borås, Sweden, are undertaking a project to turn food waste into new materials, fuel and food by growing fungi. The accumulation of waste and the depletion of natural resources are two big environmental problems. Fungi could help us tackle both by transforming waste into useful materials. Swedish researchers are looking […]

November 30, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2018

Gut Bacteria Treatment Shows Promise for Rare Genetic Kidney Condition

The Swedish biotech Oxthera reported positive preliminary Phase II results using its gut bacteria treatment, Oxabact, in patients with a rare genetic condition that causes kidney failure. The results came from an interim analysis one year into a three-year trial, where Oxthera is testing its gut microbiome treatment on patients with primary hyperoxaluria type […]

November 2, 2018 - 2 minutesmins - By Jonathan Smith

Immunicum cancer immunotherapy dendritic cell

News and Trends 16 Oct 2018

Cancer Immunotherapy Biotech Raises €34M on Nasdaq Stockholm

The Swedish biotech Immunicum has issued shares worth up to almost €34M on Nasdaq Stockholm, in an effort to accelerate the development of its cancer immunotherapy. Immunicum plans to use most of the funding to run a Phase Ib/II clinical trial that will test its lead cell therapy candidate in combination with checkpoint inhibitors to […]

October 16, 2018 - 2 minutesmins - By Jonathan Smith

Sickle Cell Disease Modus Therapeutics Cover

News and Trends 16 Jul 2018

Series A Boost for Swedish Biotech’s Sickle Cell Disease Treatment

Modus Therapeutics closed SEK 140M (€13.5M) in Series A financing to complete a Phase II study testing its sickle cell disease drug and to prepare for further clinical trials. The financing round was led by HealthCap, a European venture capital firm focused on life science investments, which will contribute SEK 60M (€5.8M). The remaining funds […]

July 16, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 9 Jul 2018

Swedish Alzheimer’s Treatment Slows the Disease in Phase II Trial

BioArctic, based in Stockholm, has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial tested the antibody in 856 patients with early-stage Alzheimer’s disease with plaques of amyloid-beta protein in their brains, which is considered a common hallmark of the disease. Results taken at […]

July 9, 2018 - 3 minutesmins - By Alexander Burik

Interview 22 Jun 2018

Swedish Biotech’s Liquid Biopsy Could Improve Accuracy of Cancer Diagnoses

Elypta is developing liquid biopsies that analyze cancer metabolism to make cancer diagnoses more accurate. Philip talked to Francesco Gatto, Elypta’s Chief Scientific Officer and a co-founder, on their technology, moving from academia to industry, and the challenges of starting a biotech company. Even though biotechs and pharma companies across the globe have been pouring […]

June 22, 2018 - 5 minutesmins - By Alexander Burik

News and Trends 11 Jun 2018

Scientists Warn CRISPR Therapy Could Cause Cancer as First Human Trials Take Place

A study at Karolinska Institutet in Sweden has revealed that CRISPR-Cas9 gene editing could favor mutations in the most common cancer-causing gene. What does it mean for the first CRISPR therapy trials in humans? CRISPR-Cas9 has taken the life sciences field by storm, making gene editing simpler and faster than ever. Although CRISPR-Cas9 gene […]

June 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 May 2018

Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes

BioLamina has partnered with Novo Nordisk to develop stem cell therapies for diabetes and other conditions using a unique cell culture matrix technology. BioLamina, based in Stockholm, is collaborating with the world-leader in diabetes treatment Novo Nordisk to develop stem cell therapies that use BioLamina’s protein cell culture matrices. BioLamina’s technology could enhance Novo Nordisk’s […]

May 16, 2018 - 2 minutesmins - By Alexander Burik

Alexion Pharmaceutical Wilson Therapeutics 2

News and Trends 11 Apr 2018

Alexion Acquires Swedish Treatment for Wilson’s Disease

Alexion Pharmaceutical intends to buy Wilson Therapeutics for nearly $1Bn. Wilson is developing a first-in-class treatment for Wilson’s disease, a rare disorder that can lead to severe liver and brain damage. Alexion Pharmaceuticals, one of the most successful companies in rare diseases and known for selling one of the most expensive drugs in the world, […]

April 11, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 26 Feb 2018

AstraZeneca Collaborates With Swedish Biotech To Speed Up Drug Development

AstraZeneca collaborates with Swedish firm Pelago Bioscience to develop assay that increases the speed and efficiency of drug development. Pelago, a Karolinska Institute spin-off, studies the interactions between a drug and its target to make the drug development process faster and more efficient. The Cellular Thermal Shift Assay (CETSA) was developed by Pelago to examine the […]

February 26, 2018 - 2 minutesmins - By Alexander Burik

autoimmune disease enzyme hansa medical 1

News and Trends 19 Feb 2018

The FDA Backs a Bacterial Enzyme to Treat a Rare Autoimmune Disease

The FDA has awarded Hansa Medical’s lead candidate for the treatment of an autoimmune disease with Orphan Drug Designation, which will support its journey through clinical development. Swedish biotech, Hansa Medical, develops enzymes that can help to control the immune system for transplantations and the treatment of autoimmune diseases. The company’s lead candidate, IdeS, has […]

February 19, 2018 - 2 minutesmins - By Alex Dale

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us